Abstract
Infarct size is a good predictor of the neurological outcome following stroke. Estimation of infarct size in the early phase following experimental stroke depends on the availability of reliable techniques that can distinguish ischemic from nonischemic tissue. The objective of this study was to provide a simple and robust method for reliable delineation of the ischemic infarct area in fresh frozen cryosections from mice subjected to focal cerebral ischemia. Mice were subjected to permanent middle cerebral artery (MCA) occlusion and euthanised after 30 min, 1, 2, 4, 6, 12 and 24 h. The size of the developing infarct was compared in parallel series of sections in situ hybridized for mRNA encoding the enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or stained with toluidine blue (TB). The infarct was clearly delineated in GAPDH mRNA in situ hybridized sections as soon as 4 h after MCA occlusion. Infarct size was similar at 4 and 6 h in GAPDH mRNA in situ hybridized sections. Sections hybridized for GAPDH mRNA showed significantly larger infarcts than sections stained with TB after 6 h but not after 24 h of ischemia. Analysis of in situ hybridized sections revealed changes in neuronal GAPDH mRNA in areas prone to undergo degeneration 30 min to 1 h after MCA occlusion, thereby preceding visible pycnosis in TB-stained sections. The results showed that in situ hybridization for GAPDH mRNA was a reliable method and superior to TB staining for precise infarct delineation prior to 6 h of permanent MCA occlusion.
Similar content being viewed by others
References
Altman FP (1976) Tetrazolium salts and formazans. Prog Histochem Cytochem 9:1–56
Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bartkowski HM (1986) Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 17:1304–1308
Berry MD (2004) Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders. J Psychiatr Neurosci 29:337–345
Carlile GW, Chalmers-Redman RM, Tatton NA, Pong A, Borden KE, Tatton WG (2000) Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol 57:2–12
Chen RW, Saunders PA, Wei H, Li Z, Seth P, Chuang DM (1999) Involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and p53 in neuronal apoptosis: evidence that GAPDH is upregulated by p53. J Neurosci 19:9654–9662
Clausen BH, Lambertsen KL, Meldgaard M, Finsen B (2005) A quantitative in situ hybridization and polymerase chain reaction study of microglial-macrophage expression of interleukin-1beta mRNA following permanent middle cerebral artery occlusion in mice. Neuroscience 132:879–892
Dastoor Z, Dreyer JL (2001) Potential role of nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase in apoptosis and oxidative stress. J Cell Sci 114:1643–1653
Gregersen R, Lambertsen K, Finsen B (2000) Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab 20:53–65
Hatfield RH, Mendelow AD, Perry RH, Alvarez LM, Modha P (1991) Triphenyltetrazolium chloride (TTC) as a marker for ischaemic changes in rat brain following permanent middle cerebral artery occlusion. Neuropathol Appl Neurobiol 17:61–67
Ishitani R, Sunaga K, Hirano A, Saunders P, Katsube N, Chuang DM (1996) Evidence that glyceraldehyde-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture. J Neurochem 66:928–935
Ishitani R, Tajima H, Takata H, Tsuchiya K, Kuwae T, Yamada M, Takahashi H, Tatton NA, Katsube N (2003) Proapoptotic protein glyceraldehyde-3-phosphate dehydrogenase: a possible site of action of antiapoptotic drugs. Prog Neuropsychopharmacol Biol Psychiatr 27:291–301
Ishitani R, Tanaka M, Sunaga K, Katsube N, Chuang DM (1998) Nuclear localization of overexpressed glyceraldehyde-3-phosphate dehydrogenase in cultured cerebellar neurons undergoing apoptosis. Mol Pharmacol 53:701–707
Joshi CN, Jain SK, Murthy PS (2004) An optimized triphenyltetrazolium chloride method for identification of cerebral infarcts. Brain Res Brain Res Protoc 13:11–17
Kharlamov A, Kim DK, Jones SC (2001) Early visual changes in reflected light on non-stained brain sections after focal ischemia mirror the area of ischemic damage. J Neurosci Methods 111:67–73
Kloss CU, Thomassen N, Fesl G, Martens KH, Yousri TA, Hamann GF (2002) Tissue-saving infarct volumetry using histochemistry validated by MRI in rat focal ischemia. Neurol Res 24:713–718
Lambertsen KL, Gregersen R, Drojdahl N, Owens T, Finsen B (2001) A specific and sensitive method for visualization of tumor necrosis factor in the murine central nervous system. Brain Res Brain Res Protoc 7:175–191
Lambertsen KL, Meldgaard M, Ladeby R, Finsen B (2005) A quantitative study of microglial-macrophage synthesis of tumor necrosis factor during acute and late focal cerebral ischemia in mice. J Cereb Blood Flow Metab 25:119–135
Liszczak TM, Hedley-Whyte ET, Adams JF, Han DH, Kolluri VS, Vacanti FX, Heros RC, Zervas NT (1984) Limitations of tetrazolium salts in delineating infarcted brain. Acta Neuropathol (Berl) 65:150–157
Moller A, Christophersen P, Drejer J, Axelsson O, Peters D, Jensen LH, Nielsen EO (1995) Pharmacological profile and anti-ischemic properties of the Ca(2+)-channel blocker NS-638. Neurol Res 17:353–360
Mulcahy NJ, Ross J, Rothwell NJ, Loddick SA (2003) Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol 140:471–476
Osborne KA, Shigeno T, Balarsky AM, Ford I, McCulloch J, Teasdale GM, Graham DI (1987) Quantitative assessment of early brain damage in a rat model of focal cerebral ischaemia. J Neurol Neurosurg Psychiatr 50:402–410
Pettigrew LC, Holtz ML, Craddock SD, Minger SL, Hall N, Geddes JW (1996) Microtubular proteolysis in focal cerebral ischemia. J Cereb Blood Flow Metab 16:1189–1202
Relton JK, Martin D, Thompson RC, Russell DA (1996) Peripheral administration of Interleukin-1 receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp Neurol 138:206–213
Saunders PA, Chalecka-Franaszek E, Chuang DM (1997) Subcellular distribution of glyceraldehyde-3-phosphate dehydrogenase in cerebellar granule cells undergoing cytosine arabinoside-induced apoptosis. J Neurochem 69:1820–1828
Sawa A, Khan AA, Hester LD, Snyder SH (1997) Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and nonneuronal cell death. Proc Natl Acad Sci USA 94:11669–11674
Shashidharan P, Chalmers-Redman RM, Carlile GW, Rodic V, Gurvich N, Yuen T, Tatton WG, Sealfon SC (1999) Nuclear translocation of GAPDH-GFP fusion protein during apoptosis. Neuroreport 10:1149–1153
Sirover MA (1997) Role of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in normal cell function and in cell pathology. J Cell Biochem 66:133–140
Sirover MA (1999) New insight into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim Biophys Acta 1432:159–184
Tanaka R, Mochizuki H, Suzuki A, Katsube N, Ishitani R, Mizuno Y, Urabe T (2002) Induction of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in rat brain after focal ischemia/reperfusion. J Cereb Blood Flow Metab 22:280–288
Taylor R, Luk YO, Chen ST, Balentine JD, Hogan EL, Hsu CY, Charleston SC (1987) Quantification of infarct area by triphenyltetrazolium chloride in a rat model. Neurology 37:82
Vogel J, Mobius C, Kuschinsky W (1999) Early delineation of ischemic tissue in rat brain cryosections by high-contrast staining. Stroke 30:1134–1141
Xu KY, Zweier JL, Becker LC (1995) Functional coupling between glycolysis and sarcoplasmic reticulum Ca2+ transport. Circ Res 77:88–97
Zivin JA (1998) Factors determining the therapeutic window for stroke. Neurology 50:599–603
Acknowledgments
This work was supported by the Faculty of Health Sciences, University of Southern Denmark - Odense, The Novo Nordic Foundation, the Hede Nielsen Foundation, The Danish MRC, and The Lundbeck Foundation. We greatly acknowledge the excellent technical assistance supported by Susanne Petersen, Inger Margrethe Rasmussen, Lene Jørgensen, Margrethe Krog, and the Laboratory of Biomedicine, University of Southern Denmark, Odense, Denmark.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Clausen, B.H., Lambertsen, K.L. & Finsen, B. Glyceraldehyde-3-phosphate dehydrogenase versus toluidine blue as a marker for infarct volume estimation following permanent middle cerebral artery occlusion in mice. Exp Brain Res 175, 60–67 (2006). https://doi.org/10.1007/s00221-006-0526-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00221-006-0526-3